Quick Answer
Inmune Bio, Inc. reported Total Revenue of $50.0 thousand for fiscal year 2025.
Inmune Bio, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $50.0K | +257.1% |
| 2024 | $14.0K | -91.0% |
| 2023 | $155.0K | -58.6% |
| 2022 | $374.0K | +106.6% |
| 2021 | $181.0K | +1545.5% |
| 2020 | $11.0K | — |
| 2018 | $0.00 | — |
| 2017 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $50.0K | +257.1% | +257.1% |
| March 31, 2024 | $14.0K | -63.2% | -67.4% |
| September 30, 2023 | $43.0K | -56.1% | -6.5% |
| June 30, 2023 | $46.0K | +187.5% | +21.1% |
| March 31, 2023 | $38.0K | -76.7% | -61.2% |
| September 30, 2022 | $98.0K | +600.0% | +512.5% |
| June 30, 2022 | $16.0K | — | -90.2% |
| March 31, 2022 | $163.0K | +3975.0% | +1064.3% |
- Inmune Bio, Inc. showed an increase of +257.1% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: